{"name":"Elicio Therapeutics","slug":"elicio-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":2301000,"revenueGrowth":-91.9,"grossMargin":0,"rdSpend":24903000,"netIncome":-39571000,"cash":25862000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2022"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ELI-002 2P","genericName":"ELI-002 2P","slug":"eli-002-2p","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ELI-002 2P","genericName":"ELI-002 2P","slug":"eli-002-2p","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE90SldBX2NuRmpucGJpeGxhb1JIbVAyZkx1MGtFZWNvUnlpRDA4TEtEVENUT3hqcDAxUFpiNTB5cGJlLWdLSjRRd3RlcGp2RWRmem9CTTdOQnh6ODBlV00zZ19xREd6R2JVQUtkQ3Bn?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Elicio Therapeutics, Inc. (ELTX) - Stock Titan","headline":"If You Invested $1,000 in Elicio Therapeutics, Inc. (ELTX)","sentiment":"neutral"},{"date":"2026-03-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-12","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxPVEhDRkFHM3VZeHd1UW0zbDk2dUQxemh6S1YxTVVRVmJVSUJnNGZkenhkei1uRjJyRDBUazc4b3NwalU3cmEwWlFQV096S1U2WVhZWUlKUXNXNHkyTUNLVE9KTnNfaGZUWUJGZXVXdjMzSlozWGRMVHMwMDNOS0FKOWhUS1EwajlqR1ZjWVFZWHNCbUtrSFgzTTN6WlVRWFZ2WEhWb3JIYzY4LVU5bjBmMGhVX0JxNjRUZFBlZUM4MlhwZkI4cUlZNkVidjNBemhqbWJUUkctU09abWk4eDdvS1hRRktvdGFsQkxPeThTWmU0d1A4elZYOGRhNlNwaXBaRGc?oc=5","date":"2026-03-09","type":"deal","source":"TipRanks","summary":"ORIC Pharmaceuticals: Differentiated PRC2 Inhibitor Rinzimetostat Mitigates Sector Safety Overhang and Supports Buy Rating - TipRanks","headline":"ORIC Pharmaceuticals: Differentiated PRC2 Inhibitor Rinzimetostat Mitigates Sector Safety Overhang and Supports Buy Rati","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-10","type":"pipeline","source":"simplywall.st","summary":"Is Elicio Therapeutics (NASDAQ:ELTX) Using Debt In A Risky Way? - simplywall.st","headline":"Is Elicio Therapeutics (NASDAQ:ELTX) Using Debt In A Risky Way?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxQUmt4T1BmOEhubUFzeHZIZEZkLWRhbmVEWl9sTkRKTzFmUzNMZmZtT1ptNkxHYjFLRE5FQXZKejAwNWIxQTRaNUpPb0oxNUtHUlkwUTAxZ1ItSVZBUW01M3N2SWt1ZTAwSUxJS2VEYlRaekE2VTlHZlZJazFoNDhPMmhYYTdvV0pyOVFsdVBMMjhZV3VMZGNuWTRvZzBNRGlGYnJjcW9TTWpkS005eFUyby13UUdMelpSTXlla0NBc3JIN2Z5WWM5ajNxOHFEOUJwUUF0dDBmYjJ0alFBSzJTMk1rV0Y5ek1xTlE?oc=5","date":"2025-11-19","type":"pipeline","source":"Elicio Therapeutics","summary":"Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer - Elicio Therapeutics","headline":"Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer","sentiment":"neutral"},{"date":"2025-11-13","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugJBVV95cUxQTEoxb25CaW9GTTF4N1JPNVNhb2RqODNtWkotQjVBTHExY1FZckFKMzFiZE9GQmhBN3Z5UkFJSWgzb2VIQnptN3hBWUt3bjU4TFpiTW5PVnBVSjB5UnN5SnNhVDM0MUo4b01QS1FYdUc0eURPNVpXYUdJZE9TdjZOUE1KRC15R0diX19WdzV2c3pRMjcyWEdvanNKVEtfMG1GTmUteUFEcmE0a2JLTWwzUXVwRllwb3dHNWdSdWVSbWV2ZlR5MS1sb0FUNE5uZjVnNFpvRDRMRV81QXFxZTRiMWxqdjRIRE42V0tBWTM5aWhvNm5RTzdiSHVyc045NjJmVmlCNFRYcm9QaDFUZ01TZm9YYWxETWlpU1d2dDE1eWVWbzVsamRYLVR6VVUxbVNfWnpjMGc2X0RXZw?oc=5","date":"2025-08-12","type":"trial","source":"Elicio Therapeutics","summary":"Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients - Elicio Thera","headline":"Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for M","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOVVBtWkRrYVNPTHl2SVFXclh1ZGtWUGxQbElLTUhRUVB3bDVKdmwyN3FNVTlGLTV2WVItRHZQVmo4ampnTTVZWHYtM281WDNlX2ZnT0JPUkstMS1WaTQ4NUdoWi1tN1M2LVBSNnl3c1d2SUtCMU5sRzI2UzY2cVI0cUY0d1Q5Rkk?oc=5","date":"2025-08-12","type":"pipeline","source":"statnews.com","summary":"Questions surround a pharma DTC company with ties to Trump Jr. - statnews.com","headline":"Questions surround a pharma DTC company with ties to Trump Jr.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQQ2dtOHUwODZ2M1hfa2RDZ0ctem4wWjZ4R1ZUUUpIY0N6X2M3aVFvc083TkhEem1wbjZyMnhjb0VDOVFhNk9sS0xWaG94aVhER3lQelRPY3U5UlQwZm81STQ2ejh5b2pOeDl3WHFJTGt5T2NFdkxUVE1EanFyMDREbDYwdlJQNUVzZlVYdnNtYmR1ci03TTNGczU0c0hkX3hZSE5sUG1pLUo1QnRFa1dtLTZjUThVZHZZLTdlaHBtWVVVU1EzOFh0SWxhMA?oc=5","date":"2025-08-12","type":"pipeline","source":"geneonline.com","summary":"BlinkRx’s Ties to Donald Trump Jr. Questioned Amid Pfizer and Elicio Therapeutics’ Cancer Research Updates - geneonline.com","headline":"BlinkRx’s Ties to Donald Trump Jr. Questioned Amid Pfizer and Elicio Therapeutics’ Cancer Research Updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9QRjdSTWxZMnM2V1lFZDVoWTMyZEIzeWJKeUdReXJULW9mUzlsZkRJUi13ZFhFODVoc25CSVdnWTA4c1dOV2VQNTJkdEl1MjNVc0VERndtMExTWERfRkZZ?oc=5","date":"2025-08-11","type":"trial","source":"Nature","summary":"Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results - Nature","headline":"Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial fi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTFBMbmNGeFo0dk9iWHdNY3N1Zm82cXp0bmlLaVU5UGhWdkhhOS16WE5NWVhlUmJMb04xeE5meWhXai1MRkNDcEpab3Exems4cW9DdkxpR2hWZ3NUV19fWmpURWd1X2JZUFNDbk5iNFBYdTc?oc=5","date":"2025-03-18","type":"pipeline","source":"Labiotech.eu","summary":"The hottest cancer vaccine companies you should know about - Labiotech.eu","headline":"The hottest cancer vaccine companies you should know about","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNUFBFamt6ZWdNLTFfU0l6VFZJZHdXLW1mR01ta0gxQlFNUmhnT2hFNlp6ZVRYR2hva21hRmxXcjlGcXRCX3RMVjRvUWdpOW1fNUlNd2U1b0w5Y09HSmNfN1ktcGNCWDhkVTZvTHVaZUFEVkhOUTdFSmJZazlmYzhrbkxoVkh4bjNHRVdwdERwMGRSWmhfNUJz?oc=5","date":"2023-01-17","type":"deal","source":"BioPharma Dive","summary":"With reverse merger, Elicio becomes latest biotech to bypass an IPO - BioPharma Dive","headline":"With reverse merger, Elicio becomes latest biotech to bypass an IPO","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":2301000,"revenuePeriod":"2022-12-31","revenueHistory":[{"value":2301000,"period":"2022-12-31"},{"value":28312000,"period":"2021-12-31"},{"value":28312000,"period":"2021-12-31"},{"value":2880000,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":24903000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-39571000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":25862000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}